Immune restoration in head and neck cancer patients via cyclo-oxygenase inhibition: An update

International Journal of Immunopathology and Pharmacology

Volumn 16, Issue 2 SUPPL., 2003, Pages 41-48

  Lang, Stephan ^b   Zeidler, R ^a  

^a Vaecgene Biotech Inc   (Germany)

^b LUDWIG MAXIMILIANS UNIVERSITY   (Germany)

Author keywords

CCR5; Cyclooxygenase; NSAIDs; Prostaglandins; Rofecoxib

Indexed keywords

4 (METHYLNITROSAMINO) 1 (3 PYRIDYL) 1 BUTANONE; ACETYLSALICYLIC ACID; BENZO[A]PYRENE; CARCINOGEN; CELECOXIB; FLOSULIDE; INDOMETACIN; N (2 CYCLOHEXYLOXY 4 NITROPHENYL)METHANESULFONAMIDE; NONSTEROID ANTIINFLAMMATORY AGENT; PROSTAGLANDIN E2; PROSTAGLANDIN SYNTHASE INHIBITOR; ROFECOXIB; SULINDAC;

ANTINEOPLASTIC ACTIVITY; CANCER ADJUVANT THERAPY; CANCER RISK; CARCINOGENESIS; CHEMOPROPHYLAXIS; CONTROLLED STUDY; DIGESTIVE SYSTEM ULCER; ENZYME ACTIVITY; ENZYME INHIBITION; ENZYME SPECIFICITY; EPIDEMIOLOGICAL DATA; ESOPHAGUS CANCER; GENE OVEREXPRESSION; GROWTH INHIBITION; HEAD AND NECK CANCER; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOMODULATION; IMMUNOSUPPRESSIVE TREATMENT; IN VITRO STUDY; IN VIVO STUDY; INHIBITION KINETICS; LONG TERM CARE; MOLECULAR MECHANICS; PRIORITY JOURNAL; PROSTAGLANDIN SYNTHESIS; PROTEIN EXPRESSION; REVIEW; STATISTICAL SIGNIFICANCE; TUMOR GROWTH;

ANIMALS; CYCLOOXYGENASE 1; CYCLOOXYGENASE 2; CYCLOOXYGENASE 2 INHIBITORS; CYCLOOXYGENASE INHIBITORS; HEAD AND NECK NEOPLASMS; HUMANS; IMMUNOSUPPRESSIVE AGENTS; ISOENZYMES; MEMBRANE PROTEINS; PROSTAGLANDIN-ENDOPEROXIDE SYNTHASES;

EID: 0142058250     PISSN: 03946320     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (51)

1. Berlinger N.T. 1984. Deficient immunity in head and neck cancer due to excessive monocyte production of prostaglandins. Laryngoscope 94:1407.
2. Klapan I., V. Katic, F. Culo and V. Cuk. 1992. Prognostic significance of plasma prostaglandin E concentration in patients with head and neck cancer. J. Cancer Res. Clin. Oncol. 118:308.
3. Zeidler R., M. Csanady, O. Gires, S. Lang, B. Schmitt and B. Wollenberg. 2000. Tumor cell-derived prostaglandin E2 inhibits monocyte function by interfering with CCR5 and Mac-1. Faseb J. 14:661.
4. Ara G. and B.A. Teicher. 1996. Cyclooxygenase and lipoxygenase inhibitors in cancer therapy. Prostaglandins Leukot. Essent. Fatty Acids 54:3.
5. Cross D.S., J.L. Platt, S.K. Juhn, F.H. Bach and G.L. Adams 1992. Administration of a prostaglandin synthetase inhibitor associated with an increased immune cell infiltrate in squamous cell carcinoma of the head and neck. Arch. Otolaryngol. Head Neck Surg. 118:526.
6. Gao X., W. Hagmann, A. Zacharek, N. Wu, M. Lee, A.T. Porter and K.V. Honn 1997. Eicosanoids, cancer metastasis, and gene regulation: an overview. Adv. Exp. Med. Biol. 400A:545.
7. Huang M., S. Sharma, J.T. Mao and S.M. Dubinett 1996. Non-small cell lung cancer-derived soluble mediators and prostaglandin E2 enhance peripheral blood lymphocyte IL-10 transcription and protein production. J. Immunol. 157:5512.
8. Culo F., I. Klapan, V. Katic, T. Kolak and B. Bakula 1992. Production of prostaglandin E by squamous carcinoma of the head and neck and adenocarcinoma of gastrointestinal tissue. Med. Oncol. Tumor Pharmacother. 9:35.
9. Cortesina G., A. De Stefani, M. Sacchi, S. Rosso and E. Galeazzi 1993. Immunomodulation therapy for squamous cell carcinoma of the head and neck. Head Neck 15:266.
10. Vanderveen E.E., R.C. Grekin, N.A. Swanson and K. Kragballe 1986. Arachidonic acid metabolites in cutaneous carcinomas. Evidence suggesting that elevated levels of prostaglandins in basal cell carcinomas are associated with an aggressive growth pattern. Arch. Dermatol. 122:407.
11. Botha J.H., K.M. Robinson, N. Ramchurren, K. Reddi and R.J. Norman 1986. Human esophageal carcinoma cell lines: prostaglandin production, biological properties, and behavior in nude mice. J. Natl. Cancer lnst. 76:1053.
12. Fosslien E. 2000. Molecular pathology of cyclooxygenase-2 in neoplasia. Ann. Clin. Lab. Sci. 30:3.
13. Rioux N. and A. Castonguay 1999. Induction of COX expression by a tobacco carcinogen: implication in lung cancer chemoprevention. Inflamm. Res. 48 2(S):136.
14. Chan G., J.O. Boyle, E.K. Yang, F. Zhang, P.G. Sacks, J.P. Shah, D. Edelstein, R.A. Soslow, A.T. Koki, B.M. Woerner, J.L. Masferrer and A.J. Dannenberg 1999. Cyclooxygenase-2 expression is up-regulated in squamous cell carcinoma of the head and neck. Cancer Res. 59:991.
15. Azuma M., H. Yssel, J.H. Phillips, H. Spits and L.L. Lanier 1993. Functional expression of B7/BB1 on activated T lymphocytes. J. Exp. Med. 177:845.
16. Tsujii M., S. Kawano, S. Tsuji, H. Sawaoka, M. Hori and R.N. DuBois 1998. Cyclooxygenase regulates angiogenesis induced by colon cancer cells. Cell 93:705.
17. Banerjee A.G., V.K. Gopalakrishnan, I. Bhattacharya and J.K. Vishwanatha 2002. Deregulated cyclooxygenase-2 expression in oral premalignant tissues. Mol. Cancer Ther. 1:1265.
18. Nathan C.A., I.L. Leskov, M. Lin, F.W. Abreo, R. Shi, G.H. Hartman and J. Glass 2001. COX-2 expression in dysplasia of the head and neck: correlation with elF4E. Cancer 92:1888.
19. Zimmermann K.C., M. Sarbia, A.A. Weber, F. Borchard, H.E. Gabbert and K. Schror 1999. Cyclooxygenase-2 expression in human esophageal carcinoma. Cancer Res. 59:198.
20. Maaser K., P. Daubler, B. Barthel, B. Heine, B. von Lampe, H. Stein, B. Hoffmeister, H. Scherer and H. Scherubl 2003. Oesophageal squamous cell neoplasia in head and neck cancer patients: upregulation of COX-2 during carcinogenesis. Br. J. Cancer 88:1217.
21. Gallo O., A. Franchi, L. Magnelli, I. Sardi, A. Vannacci, V. Boddi, V. Chiarugi and E. Masini 2001. Cyclooxygenase-2 pathway correlates with VEGF expression in head and neck cancer. Implications for tumor angiogenesis and metastasis. Neoplasia 3:53.
22. Jaeckel E.C., S. Raja, J. Tan, S.K. Das, S.K. Dey, D.A. Girod, T.T. Tsue and T.R. Sanford 2001. Correlation of expression of cyclooxygenase-2, vascular endothelial growth factor, and peroxisome proliferator-activated receptor delta with head and neck squamous cell carcinoma. Arch. Otolaryngol. Head Neck Surg. 127:1253.
23. Nishimura G., S. Yanoma, H. Mizuno, K. Kawakami and M. Tsukuda 1999. A selective cyclooxygenase-2 inhibitor suppresses tumor growth in nude mouse xenografted with human head and neck squamous carcinoma cells. Jpn. J. Cancer Res. 90:1152.
24. Gallo O., E. Masini, B. Bianchi, L. Bruschini, M. Paglierani and A. Franchi 2002. Prognostic significance of cyclooxygenase-2 pathway and angiogenesis in head and neck squamous cell carcinoma. Hum. Pathol. 33:708.
25. Springer T.A. 1995. Traffic signals on endothelium for lymphocyte recirculation and leukocyte emigration. Annu. Rev. Physiol. 57:827.
26. Rollins B.J. 1997. Chemokines. Blood 90:909.
27. Vaddi K. and R.C. Newton 1994. Regulation of monocyte integrin expression by beta-family chemokines. J. Immunol. 153:4721.
28. Murphy P.M. 1994. The molecular biology of leukocyte chemoattractant receptors. Annu. Rev. Immunol. 12:593.
29. Thivierge M., C. Le Gouill, M.J. Tremblay, J. Stankova and M. Rola-Pleszczynski 1998. Prostaglandin E2 induces resistance to human immunodeficiency virus-1 infection in monocyte-derived macrophages: downregulation of CCR5 expression by cyclic adenosine monophosphate. Blood 92:40.
30. Lang S., L. Lauffer, C. Clausen, I. Lohr, B. Schmitt, D. Holzel, B. Wollenberg, O. Gires, E. Kastenbauer and R. Zeidler 2003. Impaired monocyte function in cancer patients: restoration with a cyclooxygenase-2 inhibitor. FASEB J. 17:286.
31. Shiff S.J. and B. Rigas 1997. Nonsteroidal antiinflammatory drugs and colorectal cancer: evolving concepts of their chemopreventive actions. Gastroenterology 113:1992.
32. Zhang X., S.G. Morham, R. Langenbach and D.A. Young 1999. Malignant transformation and antineoplastic actions of nonsteroidal antiinflammatory drugs (NSAIDs) on cyclooxygenase-null embryo fibroblasts. J. Exp. Med. 190:451.
33. Hirsch B., J.T. Johnson, B.S. Rabin and P.B. Thearle 1983. Immunostimulation of patients with head and neck cancer. In vitro and preliminary clinical experiences. Arch. Otolaryngol. 109:298.
34. Cortesina G., A. De Stefani, M. Giovarelli, M.G. Barioglio, G.P. Cavallo, C. Jemma and G. Forni 1988. Treatment of recurrent squamous cell carcinoma of the head and neck with low doses of interleukin-2 injected perilymphatically. Cancer 62:2482.
35. Hadden J.W., J. Endicott, P. Baekey, P. Skipper and E.M. Hadden 1994. Interleukins and contrasuppression induce immune regression of head and neck cancer. Arch. Otolaryngol Head Neck Surg. 120:395.
36. Bosetti C., S. Gallus and C. La Vecchia 2002. Aspirin and cancer risk: an update to 2001. Eur. J. Cancer Prev. 11:535.
37. Balkwill F. and A. Mantovani 2001. Inflammation and cancer: back to Virchow? Lancet 357:539.
38. Funkhouser E.M. and G.B. Sharp 1995. Aspirin and reduced risk of esophageal carcinoma. Cancer 76:1116.
39. Cullen L., L. Kelly, S.O. Connor and D.J. Fitzgerald 1998. Selective cyclooxygenase-2 inhibition by nimesulide in man. J. Pharmacol. Exp. Ther. 287:578.
40. Steinbach G., P.M. Lynch, R.K. Phillips, M.H. Wallace, E. Hawk, G.B. Gordon, N. Wakabayashi, B. Saunders, Y. Shen, T. Fujimura, L.K. Su and B. Levin 2000. The effect of celecoxib, a cyclooxygenase-2 inhibitor, in familial adenomatous polyposis. N. Engl. J. Med. 342:1946.
41. Giardiello F.M., V.W. Yang, L.M. Hylind, A.J. Krush, G.M. Petersen, J.D. Trimbath, S. Piantadosi, E. Garrett, D.E. Geiman, W. Hubbard, G.J. Offerhaus and S.R. Hamilton 2002. Primary chemoprevention of familial adenomatous polyposis with sulindac. N. Engl. J. Med. 346:1054.
42. Tsujii M. and R.N. DuBois 1995. Alterations in cellular adhesion and apoptosis in epithelial cells overexpressing prostaglandin endoperoxide synthase 2. Cell 83:493.
43. Zweifel B.S., T.W. Davis, R.L. Ornberg and J.L. Masferrer 2002. Direct evidence for a role ot cyclooxygenase 2-derived prostaglandin E2 in human head and neck xenograft tumors. Cancer Res. 62:6706.
44. Sumitani K., R. Kamijo, T. Toyoshima, Y. Nakanishi, K. Takizawa, M. Hatori and M. Nagumo 2001. Specific inhibition of cyclooxygenase-2 results in inhibition of proliferation of oral cancer cell lines via suppression of prostaglandin E2 production. J. Oral Pathol. Med. 30:41.
45. Shiotani H., A. Denda, K. Yamamoto, W. Kitayama, T. Endoh, Y. Sasaki, N. Tsutsumi, M. Sugimura and Y. Konishi 2001. Increased expression of cyclooxygenase-2 protein in 4-nitroquinoline-1-oxide-induced rat tongue carcinomas and chemopreventive efficacy of a specific inhibitor, nimesulide. Cancer Res. 61:1451.
46. Wang Z., C.F. Fuentes and S.M. Shapshay 2002. Antiangiogenic and chemopreventive activities of celecoxib in oral carcinoma cell. Laryngoscope 112:839.
47. Wang Z., C.F. Fuentes and S.M. Shapshay 2003. Cancer " photo-chemoprevention" with pulsed dye laser and celecoxib. Lasers Surg. Med. 32:180.
48. El-Bayoumy K., M. Iatropoulos, S. Amin, D. Hoffmann and E.L. Wynder 1999. Increased expression of cyclooxygenase-2 in rat lung tumors induced by the tobacco-specific nitrosamine 4-(methylnitrosamino)-4-(3-pyridyl)-1-butanone: the impact of a high-fat diet. Cancer Res. 59:1400.
49. Pyo H., H. Choy, G.P. Amorino, J.S. Kim, Q. Cao, S.K. Hercules and R.N. DuBois 2001. A selective cyclooxygenase-2 inhibitor, NS-398, enhances the effect of radiation in vitro and in vivo preferentially on the cells that express cyclooxygenase-2. Clin. Cancer Res. 7:2998.
50. Milas L. 2001. Cyclooxygenase-2 (COX-2) enzyme inhibitors as potential enhancers of tumor radioresponse. Semin. Radiat. Oncol. 11:290.
51. Shah T., S. Ryu, H.J. Lee, S. Brown and J.H. Kim 2002. Pronounced radiosensitization of cultured human cancer cells by COX inhibitor under acidic microenvironment. Int. J. Radiat. Oncol. Biol. Phys. 53:1314.